Clinical Trial Update: KHK2455 (IDO Inhibitor) Plus Avelumab in Adult Subjects With Advanced Bladder Cancer [Phase 1]

View source ↗

Summary

Phase 1 study of KHK2455 (IDO inhibitor) plus Avelumab in adults with advanced urothelial carcinoma has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Urothelial Carcinoma

Drugs mentioned

• Avelumab (avelumab)
• KHK2455

Snippet

Sponsor: Kyowa Kirin, Inc. | Conditions: Urothelial Carcinoma | Phase 1 | Status: TERMINATED